US 9,937,191 B2
Inhibition of HIV infection through chemoprophylaxisGeneral
US 9,937,191 B2
Inhibition of HIV infection through chemoprophylaxis
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Shengjun Wang
Art Unit:
1627 Organic Chemistry
Agent:
Inventors:
Thomas M. Folks; Ronald A. Otten; Walid Heneine; Robert Janssen; Jose Gerardo Garcia Lerma
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Priority:
02/03/06
Filed:
01/13/17
Granted:
04/10/18
Expiration:
02/03/26
Abstract
A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.
Cooperative Patent Classification (CPC)
A61A61K31/7072A61P31/18A61K